573 related articles for article (PubMed ID: 30861560)
1. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
3. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
4. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
5. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
[TBL] [Abstract][Full Text] [Related]
7. [Endocrine side effects of checkpoint inhibitors].
Chen WJY; Krul-Poel YHM; Roth C; Labots M; van den Eertwegh AJM; Dreijerink KMA
Ned Tijdschr Geneeskd; 2019 Oct; 163():. PubMed ID: 31714042
[TBL] [Abstract][Full Text] [Related]
8. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
9. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D
J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245
[TBL] [Abstract][Full Text] [Related]
10. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review.
Yoo WS; Ku EJ; Lee EK; Ahn HY
Endocrinol Metab (Seoul); 2023 Dec; 38(6):750-759. PubMed ID: 37956967
[TBL] [Abstract][Full Text] [Related]
12. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.
Lu J; Li L; Lan Y; Liang Y; Meng H
Cancer Med; 2019 Dec; 8(18):7503-7515. PubMed ID: 31679184
[TBL] [Abstract][Full Text] [Related]
14. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
15. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
17. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
18. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
